Why the study?
What is the risk of myocarditis associated with clozapine use and how should it be managed?
What is the risk of myocarditis associated with clozapine use and how should it be managed?
Clozapine carries a risk of potentially fatal myocarditis and cardiomyopathy, necessitating clinical awareness and appropriate management strategies.
Answers are grounded in this paper and cite their sources.
Requires cardiac monitoring with clozapine; extends observational evidence but leaves optimal surveillance open.
Clozapine, an atypical antipsychotic, is a dibenzodiazepine derivative and its therapeutic effects are probably mediated by dopaminergic and serotonergic activity. In accordance to several studies, it appears to be the most effective antipsychotic drug for treatment-resistant schizophrenia. Moreover, clozapine appears to be particularly beneficial in patients with schizophrenia who are suicidal and in those with comorbid substance use disorder. However, despite its efficacy, the general use of clozapine in clinical practice is somewhat limited because of the risk of several serious adverse effects such as agranulocytosis and thromboembolism. Clozapine may be associated with fatal myocarditis and cardiomyopathy in physically healthy young adults. Consequently, the FDA and the drug's manufacturer have strengthened warnings to include that a potentially fatal myocarditis may occur when taking clozapine. In the present paper the literature on clozapine-related myocardis will be reviewed and practical advice will be given concerning the diagnosis and management of such potentially fatal adverse effect.
No takes yet. Share an insight, caveat, or question.
Berardis et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: